Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why? Stefan LeuchtS. Z. LevineT. A. Furukawa Editorial 03 September 2018 Pages: 621 - 623
Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis Marc KrauseYikang ZhuStefan Leucht Original Paper 24 January 2018 Pages: 625 - 639
Neural substrate of unrelenting negative symptoms in schizophrenia: a longitudinal resting-state fMRI study Mingli LiWei DengTao Li Original Paper 11 November 2017 Pages: 641 - 651
Auditory feature perception and auditory hallucinatory experiences in schizophrenia spectrum disorder Ashley M. Schnakenberg MartinLisa BartolomeoBrian F. O’Donnell Original Paper 21 September 2017 Pages: 653 - 661
Treatment of auditory hallucinations with bilateral theta burst stimulation (cTBS): protocol of a randomized, double-blind, placebo-controlled, multicenter trial Christian PlewniaBettina BrendelAndreas J. Fallgatter Original Paper 09 December 2017 Pages: 663 - 673
Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis Arnaud LeroyFlorian NaudetAli Amad Original Paper 21 June 2017 Pages: 675 - 687
Olfactory deficits in individuals at risk for psychosis and patients with schizophrenia: relationship with socio-cognitive functions and symptom severity Tsutomu TakahashiMihoko NakamuraMichio Suzuki Original Paper 25 October 2017 Pages: 689 - 698
Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study A. M. Sánchez-TorresL. Moreno-IzcoPEPs group Original Paper 21 November 2017 Pages: 699 - 711
Self-disorders in schizophrenia-spectrum disorders: a 5-year follow-up study Julie NordgaardLars Siersbæk NilssonJosef Parnas Original Paper Open access 01 September 2017 Pages: 713 - 718
Increased pericardial adipose tissue and cardiometabolic risk in patients with schizophrenia versus healthy controls J. RuppertD. HartungK. G. Kahl Original Paper 23 November 2017 Pages: 719 - 725
Cannabinoids and glial cells: possible mechanism to understand schizophrenia Valéria de AlmeidaDaniel Martins-de-Souza Invited Review 01 February 2018 Pages: 727 - 737